Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

Safety profile of subcutaneous trastuzumab for the treatment of patients with HER2-positive early or locally advanced breast cancer: primary analysis of the SCHEARLY study.

Zambetti M, Montemurro F, Morandi P, Zamagni C, Brandes AA, Bisagni G, Cagossi K, Bengala C, Gori S, Iannacone C, Stell A, Gianni L.

Eur J Cancer. 2018 Dec;105:61-70. doi: 10.1016/j.ejca.2018.09.034. Epub 2018 Nov 3.

PMID:
30396014
2.

Mechanical characterization and force-displacement hysteretic curves from in-plane cyclic tests on strong masonry infills.

Morandi P, Hak S, Magenes G.

Data Brief. 2017 Dec 14;16:886-904. doi: 10.1016/j.dib.2017.12.015. eCollection 2018 Feb.

3.

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial.

Gianni L, Pienkowski T, Im YH, Tseng LM, Liu MC, Lluch A, Starosławska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi GV, Magazzù D, McNally V, Douthwaite H, Ross G, Valagussa P.

Lancet Oncol. 2016 Jun;17(6):791-800. doi: 10.1016/S1470-2045(16)00163-7. Epub 2016 May 11.

PMID:
27179402
4.

Is it possible to teach pain therapy playing basketball?

Porzio G, Verna L, Giusti R, Marchetti P, Morandi P, Ficorella C.

Ann Palliat Med. 2016 Jan;5(1):71-3. doi: 10.3978/j.issn.2224-5820.2015.12.02. No abstract available.

5.

Notch Cooperates with Survivin to Maintain Stemness and to Stimulate Proliferation in Human Keratinocytes during Ageing.

Palazzo E, Morandi P, Lotti R, Saltari A, Truzzi F, Schnebert S, Dumas M, Marconi A, Pincelli C.

Int J Mol Sci. 2015 Nov 3;16(11):26291-302. doi: 10.3390/ijms161125948.

6.

Organ culture and Reflectance Confocal Microscopy as new integrated tools for barrier rescue studies in inflammatory skin diseases.

Petrachi T, Lotti R, Palazzo E, Truzzi F, Saltari A, Morandi P, Ciardo S, Pellacani G, Pincelli C, Marconi A.

Exp Dermatol. 2015 Dec;24(12):980-2. doi: 10.1111/exd.12823. Epub 2015 Oct 2. No abstract available.

PMID:
26268366
7.

Isolation and characterization of squamous cell carcinoma-derived stem-like cells: role in tumor formation.

Dallaglio K, Petrachi T, Marconi A, Truzzi F, Lotti R, Saltari A, Morandi P, Puviani M, Maiorana A, Roop DR, Pincelli C.

Int J Mol Sci. 2013 Sep 26;14(10):19540-55. doi: 10.3390/ijms141019540.

8.

Factors influencing the prescription of allergen immunotherapy: the allergen immunotherapy decision analysis (AIDA) study.

Frati F, Incorvaia C, Cadario G, Fiocchi A, Senna GE, Rossi O, Romano A, Scala E, Romano C, Ingrassia A, Zambito M, Dell'albani I, Scurati S, Passalacqua G, Canonica GW; AIDA Study Group.

Eur Ann Allergy Clin Immunol. 2013 Oct 1;45 Suppl 2:11-6.

PMID:
24129083
9.

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.

Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, Lluch A, Staroslawska E, de la Haba-Rodriguez J, Im SA, Pedrini JL, Poirier B, Morandi P, Semiglazov V, Srimuninnimit V, Bianchi G, Szado T, Ratnayake J, Ross G, Valagussa P.

Lancet Oncol. 2012 Jan;13(1):25-32. doi: 10.1016/S1470-2045(11)70336-9. Epub 2011 Dec 6.

PMID:
22153890
10.

Pathological complete response rates following different neoadjuvant chemotherapy regimens for operable breast cancer according to ER status, in two parallel, randomized phase II trials with an adaptive study design (ECTO II).

Zambetti M, Mansutti M, Gomez P, Lluch A, Dittrich C, Zamagni C, Ciruelos E, Pavesi L, Semiglazov V, De Benedictis E, Gaion F, Bari M, Morandi P, Valagussa P, Luca G.

Breast Cancer Res Treat. 2012 Apr;132(3):843-51. doi: 10.1007/s10549-011-1660-6. Epub 2011 Jul 13.

PMID:
21750964
11.

Manipulating the chemokine-chemokine receptor network to treat cancer.

Ruffini PA, Morandi P, Cabioglu N, Altundag K, Cristofanilli M.

Cancer. 2007 Jun 15;109(12):2392-404. Review.

12.
13.

Advances in the treatment of breast cancer.

Morandi P.

Womens Health (Lond). 2005 Nov;1(3):359-63. doi: 10.2217/17455057.1.3.359. No abstract available.

PMID:
19803877
14.

Rationale for the use of trastuzumab in patients with cerebral metastases who previously receive trastuzumab-based therapy for metastatic breast cancer.

Altundag K, Altundag O, Atik MA, Morandi P, Gunduz M.

Breast. 2005 Oct;14(5):425. No abstract available.

PMID:
16216749
15.

Factors predictive of distant metastases in patients with breast cancer who have a pathologic complete response after neoadjuvant chemotherapy.

Gonzalez-Angulo AM, McGuire SE, Buchholz TA, Tucker SL, Kuerer HM, Rouzier R, Kau SW, Huang EH, Morandi P, Ocana A, Cristofanilli M, Valero V, Buzdar AU, Hortobagyi GN.

J Clin Oncol. 2005 Oct 1;23(28):7098-104.

PMID:
16192593
16.

Breast cancer molecular subtypes respond differently to preoperative chemotherapy.

Rouzier R, Perou CM, Symmans WF, Ibrahim N, Cristofanilli M, Anderson K, Hess KR, Stec J, Ayers M, Wagner P, Morandi P, Fan C, Rabiul I, Ross JS, Hortobagyi GN, Pusztai L.

Clin Cancer Res. 2005 Aug 15;11(16):5678-85.

17.

The role of insulin-like growth factor-I receptor in the development of Herceptin resistance.

Altundag K, Altundag O, Morandi P, Ozcakar B, Boruban C, Tanner M, Isola J.

Mol Cancer Ther. 2005 Jul;4(7):1136; author reply 1136. No abstract available.

18.

Smoking status and adenocarcinoma histology may explain an improved survival in the female non-small cell lung cancer patients.

Altundag K, Altundag O, Morandi P, Gunduz M.

Lung Cancer. 2005 Jul;49(1):137; author reply 139. No abstract available.

PMID:
15949603
19.

Association between epidermal growth factor receptor mutation and improved survival in never-smokers with primary adenocarcinoma of the lung.

Altundag O, Altundag K, Morandi P, Gunduz M.

Chest. 2005 Jun;127(6):2292. No abstract available.

PMID:
15947360
20.

Treatment of thymoma and prognostic factors: In regard to Zhu et al. (Int J Radiat Oncol Biol Phys 2004;60:1113-1119).

Altundag K, Morandi P, Altundag O, Yigitbasi OG.

Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):942. No abstract available.

PMID:
15936584

Supplemental Content

Loading ...
Support Center